Positive News Sentiment NASDAQ:TNDM Tandem Diabetes Care - TNDM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Tandem Diabetes Care, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $45.04 +0.06 (+0.13%) (As of 02/3/2023 05:07 PM ET) Add Compare Share Share Today's Range$44.18▼$45.9550-Day Range$39.36▼$46.5052-Week Range$33.51▼$124.03Volume995,158 shsAverage Volume1.00 million shsMarket Capitalization$2.90 billionP/E RatioN/ADividend YieldN/APrice Target$75.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Tandem Diabetes Care MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside67.4% Upside$75.50 Price TargetShort InterestBearish8.10% of Shares Sold ShortDividend StrengthN/ASustainability-0.64Upright™ Environmental ScoreNews Sentiment1.64Based on 5 Articles This WeekInsider TradingSelling Shares$402,500 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.77) to ($0.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector217th out of 1,029 stocksSurgical & Medical Instruments Industry22nd out of 107 stocks 3.3 Analyst's Opinion Consensus RatingTandem Diabetes Care has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $75.50, Tandem Diabetes Care has a forecasted upside of 67.4% from its current price of $45.10.Amount of Analyst CoverageTandem Diabetes Care has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.10% of the outstanding shares of Tandem Diabetes Care have been sold short.Short Interest Ratio / Days to CoverTandem Diabetes Care has a short interest ratio ("days to cover") of 4.5.Change versus previous monthShort interest in Tandem Diabetes Care has recently decreased by 2.07%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldTandem Diabetes Care does not currently pay a dividend.Dividend GrowthTandem Diabetes Care does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreTandem Diabetes Care has received a 80.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Insulin pumps" product. See details.Environmental SustainabilityThe Environmental Impact score for Tandem Diabetes Care is -0.64. Previous Next 3.1 News and Social Media Coverage News SentimentTandem Diabetes Care has a news sentiment score of 1.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Tandem Diabetes Care this week, compared to 2 articles on an average week.Search InterestOnly 6 people have searched for TNDM on MarketBeat in the last 30 days. This is a decrease of -14% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Tandem Diabetes Care to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tandem Diabetes Care insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $402,500.00 in company stock.Percentage Held by InsidersOnly 2.20% of the stock of Tandem Diabetes Care is held by insiders.Percentage Held by Institutions96.50% of the stock of Tandem Diabetes Care is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Tandem Diabetes Care are expected to grow in the coming year, from ($0.77) to ($0.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tandem Diabetes Care is -42.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tandem Diabetes Care is -42.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTandem Diabetes Care has a P/B Ratio of 6.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Tandem Diabetes Care (NASDAQ:TNDM) StockTandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006, and is headquartered in San Diego, CA.Read More Receive TNDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter. Email Address TNDM Stock News HeadlinesJanuary 29, 2023 | americanbankingnews.comWolfe Research Begins Coverage on Tandem Diabetes Care (NASDAQ:TNDM)January 23, 2023 | finance.yahoo.comTandem Diabetes Care Completes Acquisition of Insulin Patch Pump Developer, AMF MedicalFebruary 3, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 19, 2023 | finance.yahoo.comTandem Diabetes Care to Announce Fourth Quarter and Full Year 2022 Financial Results on February 22, 2023January 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM) and Exact Sciences (EXAS)January 10, 2023 | msn.comTandem Diabetes stock rises after preliminary sales hit reduced guidance, 2023 forecast exceeds markJanuary 10, 2023 | markets.businessinsider.comTandem Diabetes Care Reports Q4 Preliminary SalesJanuary 10, 2023 | finance.yahoo.comTandem Diabetes Care Reports Preliminary, Unaudited 2022 Sales and Reaffirms 2023 OutlookFebruary 3, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 7, 2023 | benzinga.comTandem Diabetes Care Stock (NASDAQ:TNDM), Quotes and News SummaryJanuary 3, 2023 | finance.yahoo.comTandem Diabetes Care to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 19, 2022 | nz.finance.yahoo.comTandem (TNDM) to Expand Global Insulin Pump Base With New BuyDecember 13, 2022 | finance.yahoo.comTandem Diabetes Acquires Swiss Based Insulin Patch Pump DeveloperDecember 13, 2022 | finance.yahoo.comTandem Diabetes Care (TNDM) Stock Declined in Q3 Due to CompetitionDecember 13, 2022 | msn.comTandem Diabetes Care to acquire Swiss insulin patch pump developerDecember 13, 2022 | finance.yahoo.comTandem Diabetes Care to Acquire Insulin Patch Pump Developer, AMF MedicalDecember 13, 2022 | finance.yahoo.comTandem Diabetes to acquire Swiss insulin pump maker AMF MedicalDecember 5, 2022 | seekingalpha.comTandem Diabetes Care: Undervalued Technology LeaderNovember 24, 2022 | finance.yahoo.comIs There An Opportunity With Tandem Diabetes Care, Inc.'s (NASDAQ:TNDM) 49% Undervaluation?November 16, 2022 | finance.yahoo.comTandem Diabetes Care Earns Great Place to Work Certification™November 10, 2022 | finance.yahoo.comTandem Diabetes Care Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ TechnologyNovember 7, 2022 | finance.yahoo.comTandem Diabetes (TNDM) Q3 Earnings Miss, Sales View CutNovember 5, 2022 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)November 3, 2022 | marketwatch.comTandem Diabetes Shares Hit Fresh 52-Week Low After 3Q Update >TNDMNovember 3, 2022 | finance.yahoo.comTandem Diabetes Shares Slump After Dismal Annual OutlookNovember 3, 2022 | investing.comTandem Diabetes Care PT Lowered to $70 at Piper SandlerNovember 2, 2022 | finance.yahoo.comTandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Misses Revenue EstimatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TNDM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tandem Diabetes Care and its competitors with MarketBeat's FREE daily newsletter. Email Address TNDM Company Calendar Last Earnings11/03/2021Today2/03/2023Next Earnings (Confirmed)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TNDM CUSIPN/A CIK1438133 Webwww.tandemdiabetes.com Phone(858) 366-6900FaxN/AEmployees2,000Year Founded2006Price Target and Rating Average Stock Price Forecast$75.50 High Stock Price Forecast$130.00 Low Stock Price Forecast$43.00 Forecasted Upside/Downside+67.6%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$15.57 million Net Margins-8.59% Pretax Margin-8.30% Return on Equity-8.34% Return on Assets-3.63% Debt Debt-to-Equity Ratio0.67 Current Ratio4.81 Quick Ratio4.20 Sales & Book Value Annual Sales$702.80 million Price / Sales4.12 Cash Flow$0.56 per share Price / Cash Flow79.92 Book Value$6.82 per share Price / Book6.60Miscellaneous Outstanding Shares64,300,000Free Float62,884,000Market Cap$2.90 billion OptionableOptionable Beta0.79 Social Links Key ExecutivesJohn F. SheridanPresident, Chief Executive Officer & DirectorDavid B. BergerChief Operating Officer, EVP & Assistant SecretaryLeigh A. VossellerCFO, Treasurer, Principal Accounting Officer & EVPManuel JaimeSenior Vice President-Technology & Digital HealthMichael MichaudVice President-Research & DevelopmentKey CompetitorsNuVasiveNASDAQ:NUVAGlaukosNYSE:GKOSAxonicsNASDAQ:AXNXInari MedicalNASDAQ:NARIiRhythm TechnologiesNASDAQ:IRTCView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCSold 39,015 shares on 2/3/2023Ownership: 0.278%Simplex Trading LLCBought 12,400 shares on 2/2/2023Ownership: 0.000%AtonRa PartnersSold 3,543 shares on 2/2/2023Ownership: 0.013%ProShare Advisors LLCBought 402 shares on 2/2/2023Ownership: 0.008%Nisa Investment Advisors LLCBought 512 shares on 2/2/2023Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions TNDM Stock - Frequently Asked Questions Should I buy or sell Tandem Diabetes Care stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" TNDM shares. View TNDM analyst ratings or view top-rated stocks. What is Tandem Diabetes Care's stock price forecast for 2023? 9 Wall Street analysts have issued 12-month price objectives for Tandem Diabetes Care's stock. Their TNDM share price forecasts range from $43.00 to $130.00. On average, they predict the company's share price to reach $75.50 in the next year. This suggests a possible upside of 67.6% from the stock's current price. View analysts price targets for TNDM or view top-rated stocks among Wall Street analysts. How have TNDM shares performed in 2023? Tandem Diabetes Care's stock was trading at $44.95 at the start of the year. Since then, TNDM shares have increased by 0.2% and is now trading at $45.04. View the best growth stocks for 2023 here. When is Tandem Diabetes Care's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our TNDM earnings forecast. How can I listen to Tandem Diabetes Care's earnings call? Tandem Diabetes Care will be holding an earnings conference call on Wednesday, February 22nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Tandem Diabetes Care's earnings last quarter? Tandem Diabetes Care, Inc. (NASDAQ:TNDM) announced its quarterly earnings data on Wednesday, November, 3rd. The medical device company reported $0.09 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.01. The medical device company had revenue of $179.63 million for the quarter, compared to analyst estimates of $172.80 million. Tandem Diabetes Care had a negative net margin of 8.59% and a negative trailing twelve-month return on equity of 8.34%. During the same period last year, the company earned ($0.09) earnings per share. When did Tandem Diabetes Care's stock split? Shares of Tandem Diabetes Care reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What guidance has Tandem Diabetes Care issued on next quarter's earnings? Tandem Diabetes Care updated its fourth quarter 2022 earnings guidance on Tuesday, January, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $224.00 million-$224.00 million, compared to the consensus revenue estimate of $221.56 million. What is John Sheridan's approval rating as Tandem Diabetes Care's CEO? 11 employees have rated Tandem Diabetes Care Chief Executive Officer John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among the company's employees. What other stocks do shareholders of Tandem Diabetes Care own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Block (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL). What is Tandem Diabetes Care's stock symbol? Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM." Who are Tandem Diabetes Care's major shareholders? Tandem Diabetes Care's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Stephens Investment Management Group LLC (1.53%), New York State Common Retirement Fund (0.58%), Chicago Capital LLC (0.51%), Peregrine Capital Management LLC (0.29%), Essex Investment Management Co. LLC (0.28%) and Assenagon Asset Management S.A. (0.14%). Insiders that own company stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison. View institutional ownership trends. How do I buy shares of Tandem Diabetes Care? Shares of TNDM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Tandem Diabetes Care's stock price today? One share of TNDM stock can currently be purchased for approximately $45.04. How much money does Tandem Diabetes Care make? Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $2.90 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or ($1.07) on an earnings per share basis. How many employees does Tandem Diabetes Care have? The company employs 2,000 workers across the globe. How can I contact Tandem Diabetes Care? Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for the company is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at smorrison@tandemdiabetes.com. This page (NASDAQ:TNDM) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.